Although the effects of such drugs as ACE inhibitors (ACEIs) and angiotensin-receptor blockers (ARB) on ACE2 in patients with COVID-19 remain unclear, previous findings led to increased concern that ACEIs and ARBs may increase (or decrease) mortality in patients with COVID-19 [10,11]. This evidence concerns the gene ACE and COVID-19.